Therapeutic management of cytomegalovirus infection in HIV infected patients. Curative treatment and preemptive therapy: State of the art;PRISE EN CHARGE THERAPEUTIQUE DE LA MALADIE A CYTOMEGALOVIRUS AU COURS DE L'INFECTION PAR LE VIH. DU TRAITEMENT CURATIF AU TRAITEMENT PREEMPTIF: ACQUIS ET INCERTITUDES

Presse Medicale

Volumn 27, Issue 4, 1998, Pages 181-188

  Salmon Ceron D ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE; CIDOFOVIR; FOSCARNET; GANCICLOVIR; INDINAVIR; LOBUCAVIR; VALACICLOVIR; ANTIVIRUS AGENT; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SHORT SURVEY; AIDS RELATED COMPLEX; ARTICLE; BLOOD; CYTOMEGALIC INCLUSION BODY DISEASE; FORECASTING; TREATMENT OUTCOME; VIROLOGY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FORECASTING; GANCICLOVIR; HUMANS; PROTEASE INHIBITORS; TREATMENT OUTCOME;

EID: 0032583735     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (31)

1. Matheron S, Chaput S, Gerbe J et al. Effect of protease inhibitors on the incidence of CMV retinitis in HIV-infected patients. 6th European Conference on Clinical Aspects and Treatment of HIV-infection. Hambourg, 1997 - Abstract I-232.
2. Baril L, Jouan M, Caumes E, Mengcal X, Bricaire F, Katlama C. The impact of active antiretroviral therapy on the incidence of CMV disease in AIDS patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997 - Abstract I-31.
3. Michelet C, Allavena C, Besnier JM et al. et le groupe Gérico à Rennes - Opportunistic infections occurred under protease inhibitors in HIV patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997 - Abstract I-29.
4. Duval X, Houhou N, Ecobichon JL et al. HIV-protease inhibitors decrease the risk of cytomegalovirus (CMV) disease in HIV-infected patients with CMV viremia. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997 - Abstract I-37.
5. Raffi F. Compte rendu symposium : réunite à CMV et VIH. Med Mal Infect 1997 ; 27:743-8.
6. Studies of the Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. - Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes. Ophthalmology 1994 ; 101:1250-61.
7. Martin DF, Parks DF, Mellow SD et al. Treatment of cytomegalovirus retinitis with an intraocular sustained release ganciclovir implant : a randomized controlled clinical trial. Arch Ophthalmol 1994 ; 112:1531-9.
8. Chiron Vision Vitrasert Group - A multicenter study to evaluate the safety of intravitreal ganciclovir implant (Vitrasert) in AIDS patients with newly diagnosed CMV retinitis. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 1995 (Study GCVI -601 - CMV) - Based on final report GCVI - 601 - CMV, 8 may 1995.
9. Anduze-Faris B, Fillet AM, Boukli N, Gasnault J, Lancar R, Katlama C and the neuro-CMV Study Group. - Foscarnet-ganciclovir combination for central nervous system (CNS) infection with cytomegalovirus (CMV) in HIV patients : an open pilot study (ANRS 037). 6th European Conference on Clinical Aspects and Treatment of HIV-infection. Hambourg 1997 - Abstract no 233.
10. Dieterich DJ, Poles MA, Lew EA et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis 1998 ; 167:1184-8.
11. Kuppermann BD. Compte rendu symposium : rétinite à CMV et VIH. Med Mal Infect 1997 ; 27:743-8.
12. Breton G, Crémieux AC. Le traitement des infections à cytomégalovirus au cours de l'infection à VIH. Presse Med 1996 ; 25:1967-73.
13. Monographie Vidal.
14. Crumpacker CS. Ganciclovir - Review Article. N Engl J Med 1996;335:721-8.
15. Raffi F. Ganciclovir oral en traitement de relais de la rétinite à CMV. Med Mal Infect 1997 ; 27:617-18.
16. Drew WL et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995 ; 333:615-20.
17. Denner SA, Matheron S. Cytomegalovirus retinitis in AIDS patients : a comparative study of intravenous and oral ganciclovir as maintenance therapy. AIDS 1996 ; 10(Suppl. 4):S7-11.
18. Squires KE. Oral ganciclovir for cytomegalovirus retinitis in patients with AIDS : results of two randomized studies. AIDS 1996 ; 10(Suppl. 4):S13-18.
19. Salmon D, Lacassin F, Harzic M et al. Predictive value of cytomegalovirus viremia for the occurrence of CMV Organ Involvement in AIDS. J Med Virol 1990 ; 32:160-3.
20. Spector SA, Hsia K, Crager M and Stempien MJ. The Roche cooperative oral ganciclovir study group. Impact of Oral ganciclovir on plasma cytomegalovirus DNA and development of CMV disease in advanced. AIDS. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997 - Abstract I-232.
21. Gerard L, Leport C, Flandre P et al. Cytomegalovirus (CMV) viremia and the CD4+ lymphocytes count as predictors of CMV disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997 ; 24:836-40.
22. Salmon-Céron D, Gérard L, Houhou N. CMV viral load: a prognostic factor for CMV disease or death in a phase II trial of foscarnet in HIV patients with persistant CMV viremia. 36th ICAAC, New Orleans 1996 ; abstract 188.
23. Shinkai M, Bozette SA, Powderly W, Frame P, Spector SA. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk of developing human cytomegalovirus disease. J Infect Dis 1997 ; 175:302-8.
24. Mazzuli et al. XI Conference Internationale sur le sida ; 1996.
25. Drouet E, Boibieux A, Michelson S et al. Polymerase chain reaction detection of cytomegalovirus DNA in peripheral blood leucocytes as a predictor of cytomegalovirus disease in HIV-infected patients. AIDS 1993 ; 7:665-8.
26. Rasmussen L, Morris S, Zipeto D et al. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomagalovirus retinitis. J Infect Dis 1995 ; 171:177-82.
27. Goodrich JM, Mori M, Cleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991 ; 325:1601-7.
28. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991 ; 324:1005-11.
29. Einsele H, Ehninger C, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995 ; 86:2815-20.
30. Salmon-Ceron D, Mazeron MC, Chaput S et al. Evolution of CMV blood markers in HIV infected patients receiving protease inhibitors. 5th Conference on Retroviruses and Opportunistic Infections - Chicago 1997 -Abstract 752.
31. Edmunds WJ, Beck EJ, Pillay D. Cost-benefit analysis of anti-viral options for CMV disease in AIDS patients. 37th ICAAC-Toronto 1997 - Abstract no 21.